November 28, 2007
Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune® (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naïve HIV PatientsOctober 12, 2007
Boehringer Ingelheim Receives Top Honor As World’s Most Respected Biopharmaceutical Employer in Science 2007 Top Employers SurveyOctober 10, 2007
Most Women with HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than MenOctober 5, 2007
Aptivus® (tipranavir) Capsules Granted Full Approval by the U.S. FDASeptember 17, 2007
Boehringer Ingelheim Receives 2008 Best Places to Work Corporate Equality Index Award From Human Rights CampaignSeptember 13, 2007
The Lancet publishes major Phase 3 Study on novel Oral Direct Thrombin InhibitorAugust 23, 2007
Think Women Talk about Everything? Think Again!July 18, 2007
Boehringer Ingelheim Launches National Educational Initiative to Improve Awareness and Understanding of Restless Legs Syndrome (RLS)July 11, 2007
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and HaemostasisJune 18, 2007
New data presented on Micardis® (telmisartan) tablets in hypertensive patients with type 2 diabetesJune 14, 2007
Boehringer Ingelheim Initiates SPRING Study of Aptivus® (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients